Maze Therapeutics, Inc. Common Stock

MAZE

Maze Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients with genetically defined diseases. The company's platform utilizes genetic insights to identify and target underlying disease mechanisms, aiming to create innovative therapies for rare and genetically driven conditions.

$40.32 +1.37 (3.52%)
🚫 Maze Therapeutics, Inc. Common Stock does not pay dividends

Company News

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc. • Na • January 5, 2026

Maze Therapeutics announced that CEO Jason Coloma will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The clinical-stage biopharmaceutical company is developing small molecule precision medicines for kidney and metabolic diseases, with lead programs MZE829 (Phase 2 for APOL1-mediated kidney disease) and MZE782 (...

Biotech Breakouts: 3 Stocks With Massive Upside Potential
Investing.com • Chris Markoch • September 18, 2025

The article highlights three biotech stocks with significant potential growth: Viking Therapeutics, ImmunityBio, and Maze Therapeutics, each showing promising clinical trial results and analyst optimism despite current market volatility.

VKTXIBRX

Related Companies

AllianzIM U.S. Large Cap Buffer20 May ETF
AllianzIM U.S. Large Cap Buffer20 May ETF
MAYW
TrueShares Structured Outcome (May) ETF
TrueShares Structured Outcome (May) ETF
MAYZ
M3-Brigade Acquisition V Corp. Class A Ordinary shares
MBAV
MasterBeef Group Ordinary Shares
MasterBeef Group Ordinary Shares
MB